177 related articles for article (PubMed ID: 28419676)
1. Efficacy of dacarbazine as a rescue agent for histiocytic sarcoma in dogs.
Kezer KA; Barber LG; Jennings SH
Vet Comp Oncol; 2018 Mar; 16(1):77-80. PubMed ID: 28419676
[TBL] [Abstract][Full Text] [Related]
2. Epirubicin in the treatment of canine histiocytic sarcoma: sequential, alternating and rescue chemotherapy.
Mason SL; Finotello R; Blackwood L
Vet Comp Oncol; 2018 Mar; 16(1):E30-E37. PubMed ID: 28621004
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of a combination chemotherapy protocol including lomustine and doxorubicin in canine histiocytic sarcoma.
Cannon C; Borgatti A; Henson M; Husbands B
J Small Anim Pract; 2015 Jul; 56(7):425-9. PubMed ID: 25828786
[TBL] [Abstract][Full Text] [Related]
4. Phase II, open-label trial of single-agent CCNU in dogs with previously untreated histiocytic sarcoma.
Rassnick KM; Moore AS; Russell DS; Northrup NC; Kristal O; Bailey DB; Flory AB; Kiselow MA; Intile JL
J Vet Intern Med; 2010; 24(6):1528-31. PubMed ID: 21155191
[TBL] [Abstract][Full Text] [Related]
5. Long-term survival in dogs with localized histiocytic sarcoma treated with CCNU as an adjuvant to local therapy.
Skorupski KA; Rodriguez CO; Krick EL; Clifford CA; Ward R; Kent MS
Vet Comp Oncol; 2009 Jun; 7(2):139-44. PubMed ID: 19453368
[TBL] [Abstract][Full Text] [Related]
6. Lomustine chemotherapy for the treatment of presumptive haemophagocytic histiocytic sarcoma in Flat-coated Retrievers.
Elliott J
Aust Vet J; 2018 Dec; 96(12):502-507. PubMed ID: 30478839
[TBL] [Abstract][Full Text] [Related]
7. Dacarbazine as single-agent therapy for relapsed lymphoma in dogs.
Griessmayr PC; Payne SE; Winter JE; Barber LG; Shofer FS
J Vet Intern Med; 2009; 23(6):1227-31. PubMed ID: 19709354
[TBL] [Abstract][Full Text] [Related]
8. Influence of a survivin suppressor YM155 on the chemoresistance of canine histiocytic sarcoma cells.
Yamazaki H; Takagi S; Hosoya K; Okumura M
Vet J; 2015 Sep; 205(3):375-80. PubMed ID: 26048444
[TBL] [Abstract][Full Text] [Related]
9. CCNU for the treatment of dogs with histiocytic sarcoma.
Skorupski KA; Clifford CA; Paoloni MC; Lara-Garcia A; Barber L; Kent MS; LeBlanc AK; Sabhlok A; Mauldin EA; Shofer FS; Couto CG; Sørenmo KU
J Vet Intern Med; 2007; 21(1):121-6. PubMed ID: 17338159
[TBL] [Abstract][Full Text] [Related]
10. Risk factors associated with the onset of lomustine-induced neutropenia in tumour-bearing dogs.
Treggiari E; Cossu G; Valenti P; Taylor A
Vet Comp Oncol; 2022 Sep; 20(3):577-586. PubMed ID: 35249267
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy for dogs with lymph node metastasis from histiocytic sarcomas.
Moore AS; Taylor DP; Reppas G; Frimberger AE
Aust Vet J; 2017 Jan; 95(1-2):37-40. PubMed ID: 28124419
[TBL] [Abstract][Full Text] [Related]
12. Combination of CCNU and DTIC chemotherapy for treatment of resistant lymphoma in dogs.
Flory AB; Rassnick KM; Al-Sarraf R; Bailey DB; Balkman CE; Kiselow MA; Autio K
J Vet Intern Med; 2008; 22(1):164-71. PubMed ID: 18289305
[TBL] [Abstract][Full Text] [Related]
13. Survivin suppressor (YM155) enhances chemotherapeutic efficacy against canine histiocytic sarcoma in murine transplantation models.
Yamazaki H; Takagi S; Hosoya K; Okumura M
Res Vet Sci; 2015 Apr; 99():137-44. PubMed ID: 25744435
[TBL] [Abstract][Full Text] [Related]
14. Primary pulmonary histiocytic sarcoma in dogs: A retrospective analysis of 37 cases (2000-2015).
Marlowe KW; Robat CS; Clarke DM; Taylor A; Touret M; Husbands BD; Vail DM
Vet Comp Oncol; 2018 Dec; 16(4):658-663. PubMed ID: 30246460
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the drug sensitivity and expression of 16 drug resistance-related genes in canine histiocytic sarcoma cell lines.
Asada H; Tomiyasu H; Goto-Koshino Y; Fujino Y; Ohno K; Tsujimoto H
J Vet Med Sci; 2015 Jun; 77(6):677-84. PubMed ID: 25715778
[TBL] [Abstract][Full Text] [Related]
16. Clinical characteristics and prognostic factors in dogs with histiocytic sarcomas in Japan.
Takahashi M; Tomiyasu H; Hotta E; Asada H; Fukushima K; Kanemoto H; Fujino Y; Ohno K; Uchida K; Nakayama H; Tsujimoto H
J Vet Med Sci; 2014 May; 76(5):661-6. PubMed ID: 24441652
[TBL] [Abstract][Full Text] [Related]
17. Clinical prognostic factors in canine histiocytic sarcoma.
Dervisis NG; Kiupel M; Qin Q; Cesario L
Vet Comp Oncol; 2017 Dec; 15(4):1171-1180. PubMed ID: 27334037
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes in dogs with localized splenic histiocytic sarcoma treated with splenectomy with or without adjuvant chemotherapy.
Latifi M; Tuohy JL; Coutermarsh-Ott SL; Klahn SL; Leeper H; Dervisis N
J Vet Intern Med; 2020 Nov; 34(6):2645-2650. PubMed ID: 32986268
[TBL] [Abstract][Full Text] [Related]
19. Nimustine Treatment of 11 Cases of Canine Histiocytic Sarcoma.
Tani H; Kurita S; Miyamoto R; Sawada H; Fujiwara-Igarashi A; Michishita M; Azakami D; Hasegawa D; Tamura K; Bonkobara M
J Am Anim Hosp Assoc; 2020; 56(3):146. PubMed ID: 32182105
[No Abstract] [Full Text] [Related]
20. Evaluation and comparison of outcomes in dogs with periarticular and nonperiarticular histiocytic sarcoma.
Klahn SL; Kitchell BE; Dervisis NG
J Am Vet Med Assoc; 2011 Jul; 239(1):90-6. PubMed ID: 21718201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
